Garrison Bradford & Associates’s VolitionRx Ltd VNRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-775
Closed -$47K 55
2022
Q1
$47K Hold
775
0.05% 55
2021
Q4
$49K Hold
775
0.04% 52
2021
Q3
$48K Hold
775
0.05% 51
2021
Q2
$51K Hold
775
0.05% 51
2021
Q1
$59K Hold
775
0.07% 49
2020
Q4
$60K Hold
775
0.07% 52
2020
Q3
$50K Hold
775
0.07% 51
2020
Q2
$60K Hold
775
0.09% 49
2020
Q1
$48K Hold
775
0.08% 49
2019
Q4
$73K Hold
775
0.09% 53
2019
Q3
$87K Hold
775
0.12% 50
2019
Q2
$49K Hold
775
0.06% 55
2019
Q1
$50K Hold
775
0.04% 79
2018
Q4
$28K Hold
775
0.03% 78
2018
Q3
$40K Hold
775
0.03% 78
2018
Q2
$31K Hold
775
0.03% 82
2018
Q1
$37K Hold
775
0.03% 80
2017
Q4
$46K Hold
775
0.04% 83
2017
Q3
$41K Hold
775
0.03% 81
2017
Q2
$55K Hold
775
0.05% 81
2017
Q1
$62K Hold
775
0.05% 82
2016
Q4
$71K Hold
775
0.07% 80
2016
Q3
$82K Hold
775
0.08% 82
2016
Q2
$49K Hold
775
0.05% 85
2016
Q1
$55K Hold
775
0.06% 69
2015
Q4
$70K Hold
775
0.08% 76
2015
Q3
$69K Hold
775
0.08% 82
2015
Q2
$61K Hold
775
0.06% 91
2015
Q1
$64K Buy
+775
New +$64.2K 0.06% 95

Other funds holding VNRX

Garrison Bradford & Associates's VNRX Position: Q2 2022 in Review

Garrison Bradford & Associates sold out of VolitionRx Ltd (VNRX) in Q2 2022, closing a stake of 775 shares — an estimated $47K sold.

Garrison Bradford & Associates first reported a position in VNRX in Q1 2015 and held it in 29 quarters. The position peaked at $87K in Q3 2019. 31 funds tracked by Wall St. Rank hold VNRX as of Q2 2022.

  • Garrison Bradford & Associates reported no remaining VolitionRx Ltd position as of Q2 2022 after selling out during the quarter.
  • Garrison Bradford & Associates sold 775 VolitionRx Ltd shares in Q2 2022, an estimated $47K.
  • Garrison Bradford & Associates first reported a position in VolitionRx Ltd in Q1 2015 and held it in 29 quarters.
  • Garrison Bradford & Associates's VolitionRx Ltd position peaked at $87K in Q3 2019.
  • 31 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2022.

Based on Garrison Bradford & Associates's 13F filing for Q2 2022, filed 23 Aug 2022.